1995 - Member of Academia Europaea
Internal medicine, Surgery, Lymphoma, Hodgkin's lymphoma and Chemotherapy are his primary areas of study. His Internal medicine research includes elements of Gastroenterology and Oncology. His study looks at the intersection of Surgery and topics like Refractory Hodgkin Lymphoma with DHAP and Autologous stem-cell transplantation.
His study in Lymphoma is interdisciplinary in nature, drawing from both Stage, Progressive disease and Lymphocyte. The study incorporates disciplines such as Combination chemotherapy, Quality of life and Standard treatment in addition to Hodgkin's lymphoma. His research on Chemotherapy also deals with topics like
His primary areas of study are Internal medicine, Surgery, Lymphoma, Chemotherapy and Oncology. Within one scientific family, Volker Diehl focuses on topics pertaining to Gastroenterology under Internal medicine, and may sometimes address concerns connected to Progressive disease. Volker Diehl usually deals with Lymphoma and limits it to topics linked to Cancer research and Antigen.
Volker Diehl interconnects Disease and Hodgkin lymphoma in the investigation of issues within Oncology. His ABVD course of study focuses on Dacarbazine and Vinblastine. His CD30 research includes themes of Molecular biology and Monoclonal antibody.
His scientific interests lie mostly in Internal medicine, Oncology, Surgery, ABVD and BEACOPP. His study in Internal medicine concentrates on Procarbazine, Chemotherapy, Hodgkin lymphoma, Hodgkin's lymphoma and Dacarbazine. His Chemotherapy research integrates issues from Gastroenterology, Brentuximab vedotin and Dose Reduced.
His studies in Oncology integrate themes in fields like Stage, Hematology, Immunology and Radiation therapy. His Surgery study combines topics from a wide range of disciplines, such as Standard treatment and Lymphoma. His work is dedicated to discovering how BEACOPP, Clinical endpoint are connected with Median follow-up and other disciplines.
Volker Diehl focuses on Internal medicine, Surgery, Procarbazine, Hodgkin's lymphoma and Oncology. His Internal medicine study frequently links to other fields, such as Gastroenterology. His work on Surgery deals in particular with ABVD, Regimen, Dacarbazine, Chemotherapy and Survival rate.
His study looks at the relationship between Procarbazine and fields such as BEACOPP, as well as how they intersect with chemical problems. His work carried out in the field of Hodgkin's lymphoma brings together such families of science as Progression-free survival and Standard treatment. His work in Oncology covers topics such as Hodgkin lymphoma which are related to areas like Combined modality, Translational research, Disease and Advanced disease.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Revised response criteria for malignant lymphoma
Bruce D. Cheson;Beate Pfistner;Malik E. Juweid;Randy D. Gascoyne.
Journal of Clinical Oncology (2007)
A Prognostic Score for Advanced Hodgkin's Disease
D Hasenclever;V Diehl.
The New England Journal of Medicine (1998)
Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis.
Gertrude Henle;Werner Henle;Volker Diehl.
Proceedings of the National Academy of Sciences of the United States of America (1968)
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial
Norbert Schmitz;Beate Pfistner;Michael Sextro;Markus Sieber.
The Lancet (2002)
Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study
B. Coiffier;C. Haioun;N. Ketterer;A. Engert.
Production of a monoclonal antibody specific for Hodgkin and Sternberg–Reed cells of Hodgkin's disease and a subset of normal lymphoid cells
Ulrich Schwab;Harald Stein;Johannes Gerdes;Hilmar Lemke.
Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease
Volker Diehl;Jeremy Franklin;Michael Pfreundschuh;Bernd Lathan.
The New England Journal of Medicine (2003)
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
Andreas Engert;Annette Plütschow;Hans Theodor Eich;Andreas Lohri.
The New England Journal of Medicine (2010)
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)
U. Winkler;M. Jensen;O. Manzke;H. Schulz.
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
Andreas Engert;Heinz Haverkamp;Carsten Kobe;Jana Markova.
The Lancet (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: